{"id":6091,"date":"2023-01-31T09:49:12","date_gmt":"2023-01-31T09:49:12","guid":{"rendered":"https:\/\/realheart.se\/mfn_news\/correction-the-subscription-price-for-realhearts-warrant-to1-is-sek-2-36\/"},"modified":"2023-01-31T09:49:12","modified_gmt":"2023-01-31T09:49:12","slug":"correction-the-subscription-price-for-realhearts-warrant-to1-is-sek-2-36","status":"publish","type":"mfn_news","link":"https:\/\/realheart.se\/sv\/mfn_news\/correction-the-subscription-price-for-realhearts-warrant-to1-is-sek-2-36\/","title":{"rendered":"Correction: the Subscription Price for Realhearts Warrant TO1 is SEK 2.36"},"content":{"rendered":"
Press Release 31 January, 2023<\/p>\n

Scandinavian Realheart AB ("Realheart" or the "Company"), issued during the third quarter of 2021 warrants of series 2021\/2023 TO1 ("TO1"). The subscription period runs from February 1-28, 2023. Four (4) warrants of series TO1 entitle the holder to subscribe for one (1) newly issued share in Realheart. The subscription price has been set at SEK 2.36 per share in accordance with the terms of the warrants.<\/strong><\/div>\n

The previous press release stated the subscription price to be SEK 3.37, which is the volume weighted average price for the period 9-27 January 2023. According to the terms, the correct price shall be 70 percent of the volume weighted average price during the period, which amounts to SEK 2.36. <\/span><\/span><\/p>\n

A total of 10 250 002 warrants of series TO1 are issued. Upon full exercise of the warrants, the number of shares in the company will increase from 33,183,461 by 2,562,500 shares to 35,745,961 shares, corresponding to a dilutive effect of approximately 7.2 percent of the capital and votes of Realheart. <\/span><\/span><\/p>\n

Subscription instructions <\/strong><\/span><\/span><\/p>\n

Holders whose warrants are registered with a trustee (i.e. the warrants are held in a share deposit account, ISK account or endowment insurance) subscribe and make payment in accordance with the instructions of their bank or other trustee. If you have any questions, please contact your bank\/trustee well in advance of Tuesday 28 February 2023, as different trustees have different processing times. <\/span><\/span><\/p>\n

Directly registered holders (holding on VP account) of warrants of series TO1 must notify the redemption of warrants by completing and submitting the notification form for redemption of TO1, so that it is received by the issuing institution Nordic Issuing no later than 3.00 p.m. on 28 February 2023. The notification form for directly registered holders can be downloaded from Nordic Issuing's website, https:\/\/nordic-issuing.se\/<\/a>.<\/span><\/span><\/p>\n

Issue and delivery of new shares <\/strong><\/span><\/span><\/p>\n

The outcome of the exercise of warrants of series TO1 will be announced via press release as soon as possible and is expected to take place a few days after the end of the subscription period. <\/span><\/span><\/p>\n

As soon as the issue has been registered with the Swedish Companies Registration Office and Euroclear, interim shares (IA) will be converted into ordinary shares and admitted to trading on the Nasdaq First North Growth Market. <\/span><\/span><\/p>\n

Subscription price calculated and fixed <\/strong><\/span><\/span><\/p>\n

The subscription price for TO1 was fixed on 27 January 2023 at SEK 2.36 per share in accordance with the terms of the option.\u00a0 <\/span><\/span><\/p>\n

Financial advisor and issuing agent <\/strong><\/span><\/span><\/p>\n

Skills Corporate Finance Nordic AB is the financial advisor and Nordic Issuing AB is the issuing agent to Realheart in connection with the exercise of warrants of series TO1. <\/span><\/span><\/p>\n

The warrants, with ISIN code SE0016589246, are traded on Nasdaq First North Growth Market. For more information on the warrants of series TO1, please contact Nordic Issuing. <\/span><\/span><\/p>\n

Link to document for full terms and conditions (in Swedish): https:\/\/realheart.se\/wp-content\/uploads\/2023\/01\/fullstandliga-villkor-teckningsoptioner-realheart-to1.pdf<\/a><\/span><\/span><\/p>\n

\n

For more information please contact:<\/span><\/span><\/strong><\/span><\/p>\n

Ina Laura Perkins, CEO<\/span><\/span><\/p>\n

Phone: +46(0)70 406 49 21\u00a0<\/span><\/span><\/p>\n

E-mail: inalaura.perkins@realheart.se<\/span><\/span><\/p>\n

Certified Adviser: Svensk Kapitalmarknadsgranskning AB, www.skmg.se<\/a><\/p>\n<\/div>\n

\n

Scandinavian Real Heart AB develops a total artificial heart (TAH) for implantation in patients with life-threatening heart failure. Realheart<\/em><\/span><\/span>\u00ae<\/span><\/span><\/span><\/em> TAH has a patented design that resembles that of the natural human heart. The artificial heart consists of a four-chamber system (two atria and two ventricles) designed to generate a physiological blood flow pattern that mimics the body's natural circulation.\u00a0<\/em><\/span><\/span>A unique concept in the medical technology world.<\/span><\/span><\/span><\/em><\/p>\n<\/div>\n